Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Merck has also decided to end the favezelimab clinical development program
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Subscribe To Our Newsletter & Stay Updated
